FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel azoindolizines or pharmaceutically acceptable salts thereof having Mek-kinase inhibitory activity in formula : ZA means CRA; RA means H or halogen; each of R1, R2 and R3 means H; W means: , each R4 and R5 means H; X1 represents -OR7; each R7 means C2-C12-hydroxyalkyl, 2,3-dihydroxypropyl, C2-C3-alkenoxyC1-C6-alkoxy, (2,2-dimethyl-[1,3]dioxalan-4-yl)-methyl or piperidinyl; X4 means: R6 means halogen or -SR16; R6 means halogen; p is equal to 1; R16 means C1-C12-alkyl.
EFFECT: invention relates to a pharmaceutical compositions containing these compounds, to a method of inhibiting the abnormal cell growth and the use of the compounds for preparing a drug preparation for inhibiting the abnormal cell growth.
9 cl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
AZABENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | 2007 |
|
RU2444524C2 |
AZABENZOFURANYL COMPOUNDS AND METHODS OF USE | 2007 |
|
RU2448111C2 |
8-ANILINOIMIDAZOPYRIDINES AND METHODS FOR USE THEREOF | 2008 |
|
RU2498985C2 |
ISOINDOLONES AND METHODS FOR USING THEM | 2009 |
|
RU2495028C2 |
BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | 2009 |
|
RU2509078C2 |
5-ANILINOIMIDAZOPYRIDINES AND METHODS FOR USING THEM | 2008 |
|
RU2441004C1 |
CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2678305C1 |
COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
METHODS FOR PREPARING DERIVATIVES OF 1-[2-(BENZIMIDAZOL-1-YL)QUINOLIN-8-YL]PIPERIDIN-4-YLAMINE | 2004 |
|
RU2323214C2 |
Authors
Dates
2013-05-27—Published
2008-12-19—Filed